SK Capital Partners Makes Strategic Investment in Spectrum Vascular
White Plains, NY – April 1, 2025 – Spectrum Vascular, a leading provider of vascular access and medication management solutions, is proud to announce a strategic investment by an affiliate of SK Capital Partners, a New York-based private investment firm with deep expertise in the life sciences and healthcare sectors.
This partnership marks an important milestone for Spectrum Vascular as the company continues to expand its footprint and enhance its commitment to reducing healthcare-acquired infections through advanced, patient-centered technologies. SK Capital will join Event Capital Strategies (ECS), Spectrum’s current majority investor, in a recapitalization that positions the company for long-term success. ECS will retain a significant ownership stake, ensuring strategic continuity and alignment.
Founded in 2023, Spectrum Vascular was created through the acquisition of the vascular access businesses of Cook Medical and AngioDynamics. Today, our robust portfolio of products—including the SV Spectrum™ and SV BioFlo platforms—addresses critical challenges across the continuum of vascular care. Our solutions are designed to deliver superior clinical outcomes, with technologies focused on antimicrobial protection, thrombus reduction, and ease of use for clinicians.
“We are thrilled to welcome SK Capital as a strategic partner,” said the Spectrum Vascular leadership team. “Their deep sector knowledge, global network, and operational expertise will be instrumental in accelerating our next phase of growth. Together with ECS, we are well-positioned to unlock new opportunities and deliver greater value to patients, providers, and health systems.”
“ECS and the Spectrum management team have built a platform with significant growth potential,” added Jon Borell, Managing Director at SK Capital. “We’re honored to partner with them and support Spectrum’s mission to bring cutting-edge vascular access technologies to market.”
Legal counsel was provided by Kirkland & Ellis LLP for SK Capital and Fried Frank LLP for Event Capital Strategies. Debt financing for the transaction was arranged by KeyBank, Beachpoint Direct Lending Fund, Apogem Capital, and Kayne Anderson Private Credit.
About Spectrum Vascular
Spectrum Vascular is a medical device company dedicated to improving patient outcomes through advanced vascular access and medication management technologies. Formed through the acquisitions of Cook Medical and AngioDynamics' vascular access divisions, Spectrum Vascular delivers high-performance solutions that address the most common and costly complications in vascular care. For more information, visit www.spectrumvascular.com.
About SK Capital Partners
SK Capital is a private investment firm focused on the specialty materials, ingredients, and life sciences sectors. The firm seeks to build strong, sustainable businesses through operational improvements and strategic growth. With approximately $9 billion in assets under management, SK Capital’s portfolio companies generate around $12 billion in annual revenue and employ over 25,000 people globally. Visit www.skcapitalpartners.com to learn more.
About Event Capital Strategies
Event Capital Strategies is a healthcare-focused investment firm based in New York, with a strong track record in medical technology. ECS partners closely with its portfolio companies, offering strategic and operational guidance across a range of healthcare sub-sectors. Learn more at www.eventcapitalstrategies.com.
